1397P - Chronic pleural effusion in malignancy: a single center’s ten years expertise with indwelling pleural catheters

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Palliative Care
Palliative and Supportive Care
Presenter Nikolaj Frost
Citation Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382
Authors N. Frost1, M. Brünger2, B. Temmesfeld-Wollbrück1, D. Schürmann1, N. Suttorp1
  • 1Department Of Infectious Diseases And Pneumonology, Charité Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 2Institute Of Medical Sociology And Rehabilitation Science, Charité Universitätsmedizin Berlin, 10115 - Berlin/DE

Abstract

Background

Chronic and recurrent pleural effusion (PE) in malignant diseases is a common cause of dyspnea, cough and chest pain. The vast majority is malignant pleural effusion (MPE), nevertheless disease-associated but not directly disease-caused paramalignant pleural effusions (PPE) have also been described. Talc pleurodesis had been the only treatment option for decades, while for 20 years indwelling pleural catheters (IPC) have emerged as an alternative leading to spontaneous pleurodesis without any chemical agent in 40-50%.

Methods

Our aim is to explore patient characteristics, procedural variables and outcomes in a large population of patients with IPC due to PE in malignancy. Further, our objective is to identify factors associated with outcome.

Results

From 2006 until 2016 448 IPC were inserted in 395 patients, 52 received bilateral drainages (12.7%). 77.0% of the effusions were malignant (n = 304), 14.9% paramalignant (n = 59), in 8.1% the etiology could not be clarified (n = 32). The most common underlying diseases were ovarian cancer (30.6%, 121 patients), lung cancer (23.0%, 91 patients) and breast cancer (11.4%, 45 patients). The median length of insertion was 1.2 months (0.03-23.6), the median survival time after insertion 2.4 months (lung cancer 1.6 months, ovarian cancer 2.8 months, breast cancer 4.0 months). Spontaneous pleurodesis was observed in 28.6% (128/448 catheters) and was significantly associated with overall survival (HR 0.54, 95%-CI 0.39-0.75, p 

Conclusions

In conclusion, our retrospective series is the largest to date to report on IPC in malignancy and showed a manageable safety profile. Spontaneous pleurodesis was significantly associated with survival.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Charité Universitätsmedizin Berlin

Funding

None

Disclosure

All authors have declared no conflicts of interest.